proglumide has been researched along with Obesity in 4 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Loxiglumide was administered intravenously in a dose of 10 mg/kg ideal weight/h." | 2.68 | Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women. ( Jansen, JB; Lamers, CB; Lieverse, RJ; Masclee, AA; Rovati, LC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Little, TJ | 1 |
| Horowitz, M | 1 |
| Feinle-Bisset, C | 1 |
| Lieverse, RJ | 1 |
| Masclee, AA | 1 |
| Jansen, JB | 1 |
| Rovati, LC | 1 |
| Lamers, CB | 1 |
| Niederau, C | 2 |
| Meereis-Schwanke, K | 2 |
| Klonowski-Stumpe, H | 2 |
| Herberg, L | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Risk Factors of Symptomatic Gallbladder Stone: Age-Sex Matched Case-control Study Performed in Single Institute[NCT02808546] | 342 participants (Actual) | Observational | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for proglumide and Obesity
| Article | Year |
|---|---|
Role of cholecystokinin in appetite control and body weight regulation.
Topics: Animals; Appetite; Body Weight; Cholecystokinin; Digestive System Physiological Phenomena; Energy In | 2005 |
1 trial available for proglumide and Obesity
| Article | Year |
|---|---|
Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women.
Topics: Adult; Appetite; Double-Blind Method; Female; Humans; Hunger; Infusions, Intravenous; Middle Aged; O | 1995 |
2 other studies available for proglumide and Obesity
| Article | Year |
|---|---|
CCK-resistance in Zucker obese versus lean rats.
Topics: Amylases; Animals; Capsaicin; Cholecystokinin; Eating; Female; Injections, Subcutaneous; Male; Obesi | 1997 |
Long-term effects of CCK-agonist and -antagonist on food intake and body weight in Zucker lean and obese rats.
Topics: Animals; Body Weight; Ceruletide; Cholecystokinin; Drug Resistance; Eating; Female; Male; Obesity; O | 1998 |